Dr. Vidula is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit Street
Boston, MA 02114Phone+1 617-724-4000
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2013 - 2016
Northwestern University The Feinberg School of MedicineClass of 2010
Certifications & Licensure
CA State Medical License 2013 - Present
MA State Medical License 2016 - 2025
IL State Medical License 2010 - 2013- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease Start of enrollment: 2017 Sep 02
- Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial Start of enrollment: 2021 Nov 18
Publications & Presentations
PubMed
- 14 citationsReceptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in ...Neelima Vidula, Christina Yau, Jiali Li, Laura J. Esserman, Hope S. Rugo
Breast Cancer Research and Treatment. 2017-06-02 - 24 citationsNTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesChristian Rolfo, Alexander Drilon, David S. Hong, Caroline E. McCoach, Afshin Dowlati
British Journal of Cancer. 2021-09-03 - 45 citationsClinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience.Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti
Journal of the National Comprehensive Cancer Network. 2021-03-24
Lectures
- Glutaminase (GLS) expression in primary breast cancer (BC): Correlations with clinical and tumor characteristics.2019 ASCO Annual Meeting - 6/1/2019
- Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic b...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast ca...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Educated Affected Person® Metastatic Breast Most Cancers Summit HER2 and Triple-Unfavorable Illness Panel: November 12, 2022November 26th, 2022- Clinical Trial: Talazoparib in BRCA1/2-Mutated Metastatic Breast CancerSeptember 20th, 2022
- Small PFS Boost with HDAC Inhibitor for Advanced HR-Positive Breast CancerDecember 8th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
